📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 20:35
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
9.5% Revenue Growth in Q1 FY27; Rs 150 Cr New Plant Commissioned for Comfy
Amrutanjan reported a 9.48% YoY increase in net sales to Rs 102.97 Cr for Q1 FY27, driven by strong performance in the Women's Hygiene segment. However, Profit After Tax (PAT) declined to Rs 4.37 Cr from Rs 8.31 Cr YoY, impacted by a Rs 2.02 Cr exceptional item related to a legacy lease dispute and increased advertisement spending (Rs 7.81 Cr). A major strategic milestone was the commissioning of a Rs 150 Cr greenfield plant in Telangana for the 'Comfy' brand, shifting production from private-label to in-house. Management maintains a double-digit growth outlook for the full year as one-time charges subside.
Confidence: HIGH
What changedThe company has transitioned from a private-label model to in-house manufacturing for its hygiene brand and has finally settled a long-standing legal dispute regarding leasehold land.
Why it mattersThe Rs 150 Cr investment in the new plant is a significant bet on the hygiene segment to reduce dependency on the core balm business (65% of revenue), which is currently facing volume pressure.
Net Sales (Q1 FY27): Rs 102.97 CrNew Plant Investment: Rs 150 CrInvestment vs TTM Revenue: ~35.2%Comfy Sales Growth: 18.14%Exceptional Item: Rs 2.02 CrAd Spend (Q1 FY27): Rs 7.81 Cr
📅 Short termProfitability may remain volatile in the coming weeks as the company absorbs the costs of the new plant and continues high marketing spends to support new launches.
📈 Long termThe shift to in-house manufacturing for Comfy is structurally positive for margins and supply chain control, potentially re-rating the business if hygiene growth sustains.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on Pain Management segment (65% revenue)
- Increased raw material and packaging costs
- Intense competition in the hygiene and beverage segments
Key Highlights
Net Sales grew 9.48% YoY to Rs 102.97 Cr in Q1 FY27.
Commissioned a Rs 150 Cr greenfield sanitary napkin facility in Telangana, representing ~35% of TTM revenue.
Women's Hygiene (Comfy) revenue grew 18.14% YoY to Rs 33.80 Cr, now contributing 33% of total sales.
Recognized an exceptional charge of Rs 2.02 Cr for a legacy lease rent dispute settled in August 2026.
New product launches (Razors and Plastry) contributed Rs 4.12 Cr to Q1 sales, with a full-year target of Rs 25 Cr.
👀 What to Watch
Monitor the capacity utilization and margin profile of the new Telangana plant, and watch for a recovery in the core Pain Management segment which saw flat growth (+0.51%) this quarter.
Amrutanjan Q1 PAT Rises 46% to ₹4.37 Cr; Women's Hygiene Segment Grows 27% YoY
Amrutanjan Health Care reported a 9.5% YoY increase in revenue to ₹102.97 Cr for the quarter ended June 30, 2026. Net profit grew significantly by 46.6% YoY to ₹4.37 Cr, despite an exceptional charge of ₹2.03 Cr related to a retrospective lease rent dispute. Growth was primarily driven by the Women's Hygiene segment, which surged 27% to ₹36.36 Cr, while the core OTC segment remained nearly flat at ₹57.26 Cr. The company has set September 11, 2026, as the record date for the final dividend.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a strong bottom-line recovery and continued high growth in its non-core hygiene segment.
Why it mattersThe 27% growth in Women's Hygiene validates the company's diversification strategy away from its stagnant pain-balm business, which is crucial for long-term valuation re-rating.
Q1 Revenue: ₹102.97 CrQ1 PAT: ₹4.37 CrHygiene Segment Growth (YoY): 27.1%Exceptional Item (Lease Rent): ₹2.03 CrDividend Record Date: September 11, 2026PAT vs TTM PAT: ~27.3%
📅 Short termThe stock may see positive momentum due to the strong earnings beat on the profit line and robust growth in the hygiene category.
📈 Long termStructural growth depends on the successful scaling of the Hyderabad plant and the ability to maintain pricing power in the competitive hygiene and beverage segments.
⚠ Risk flags
- Stagnant growth in the core OTC segment (0.5% YoY)
- Ongoing litigation and financial demands regarding leasehold land
- Withdrawal of ESOP 2 scheme due to failure to meet turnover targets
Key Highlights
Revenue from operations increased 9.5% YoY to ₹102.97 Cr from ₹94.05 Cr.
Net Profit (PAT) grew 46.6% YoY to ₹4.37 Cr despite a ₹2.03 Cr exceptional item.
Women's Hygiene segment revenue rose to ₹36.36 Cr, now contributing ~35% of total revenue.
Core OTC segment revenue showed marginal growth of 0.5% YoY, reaching ₹57.26 Cr.
Exceptional item of ₹2.03 Cr recognized following a demand notice from the HR & CE Department regarding leasehold land.
👀 What to Watch
Watch for the margin impact as the company transitions 'Comfy' production to its in-house Hyderabad plant. Investors should also monitor if the core OTC segment can regain volume momentum in upcoming quarters.
₹150 Cr Investment: Amrutanjan Commissions New 700M Unit Sanitary Napkin Plant in Telangana
Amrutanjan Health Care has commissioned a new ₹150 crore greenfield manufacturing facility in Telangana, dedicated to its 'Comfy' sanitary napkin brand. The plant features two high-speed Japanese production lines with an annual capacity of 700 million units, marking a strategic shift from private-label outsourcing to in-house manufacturing. This investment is significant, representing approximately 40.5% of the company's current net worth (₹370 Cr). The move aims to support the Comfy brand, which already surpassed ₹130 crore in revenue during FY2025.
Confidence: HIGH
What changedAmrutanjan has transitioned from outsourcing its sanitary napkin production to a fully owned, high-capacity in-house manufacturing model.
Why it mattersThis move allows for better quality control and potentially higher margins for the Comfy brand, which is a key growth driver outside the core pain management business. The scale of the investment (40% of net worth) indicates a major commitment to diversifying the revenue base.
Total Investment: ₹150 croreInvestment vs Net Worth: ~40.5%Annual Production Capacity: 700 million unitsComfy Brand Revenue (FY25): >₹130 croreBuilt-up Area: 1.4 lakh sq. ft.
📅 Short termThe commencement of operations is a positive milestone that reduces execution risk and may provide a sentiment boost given the scale of the project.
📈 Long termThis expansion is structurally significant as it positions Amrutanjan to compete more aggressively in the high-growth feminine hygiene market with a cost-efficient, large-scale manufacturing base.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Utilization risk if sales growth does not match the large 700m unit capacity
- Increased fixed costs and depreciation following the ₹150 cr capex
- Intense competition in the hygiene segment from established FMCG players
Key Highlights
₹150 crore total investment in the new greenfield facility at Seetharampur, Telangana.
700 million sanitary napkins annual production capacity across two automated Japanese lines.
1.4 lakh sq. ft. built-up area on a 10-acre site, serving as the company's 5th plant.
Strategic transition from private-label partnerships to in-house production for the Comfy brand.
Comfy brand revenue already exceeded ₹130 crore in FY2025 prior to this expansion.
👀 What to Watch
Monitor operating profit margins (OPM) in the coming quarters to see if the shift to in-house manufacturing improves the current 11.5% margin. Investors should also track the utilization rate of the new 700 million unit capacity relative to sales growth in the feminine hygiene segment.
CARE Assigns 'CARE A; Stable' Rating to Amrutanjan; Highlights Debt-Free Status
CARE Ratings has assigned a 'CARE A; Stable' issuer rating to Amrutanjan Health Care Limited, reflecting its 133-year brand legacy and debt-free balance sheet. The company reported a Total Operating Income of ₹502.55 Cr in FY26 with a strong cash and bank balance of ₹221.85 Cr. While the core pain management segment contributes 60% of revenue, the company is diversifying into women's hygiene and beverages. A significant ₹130 Cr investment in a new Hyderabad manufacturing plant for sanitary napkins became operational in June 2026, aimed at improving margins through in-house production.
Confidence: HIGH
What changedCARE Ratings has assigned a formal investment-grade issuer rating of 'CARE A; Stable' to the company, providing an independent validation of its creditworthiness.
Why it mattersThe rating confirms the company's exceptionally strong liquidity and zero-debt status, which provides significant financial flexibility for its ongoing diversification strategy into the FMCG and hygiene sectors.
Issuer Rating: CARE A; StableFY26 Total Operating Income: ₹502.55 CrCash and Bank Balances: ₹221.85 CrHygiene Plant Capex: ₹130 CrCapex vs Net Worth: ~35.2%
📅 Short termThe rating assignment is a positive sentiment driver, confirming the company's financial stability despite recent stock price weakness.
📈 Long termThe transition from outsourced to in-house manufacturing for the hygiene segment and the expansion into personal care (razors) are structural moves to reduce dependence on the core balm business.
⚠ Risk flags
- High product concentration (60% revenue from pain relief)
- Raw material price volatility (menthol and paraffin)
- Intense competition in the FMCG sector
Key Highlights
Assigned 'CARE A; Stable' issuer rating by CARE Ratings Limited.
Maintains a debt-free capital structure with a net worth of ₹368.78 Cr as of March 31, 2026.
Total Operating Income grew 11% to ₹502.55 Cr in FY26 compared to FY25.
Invested ₹130 Cr in a new sanitary napkin plant in Hyderabad, funded entirely by internal accruals.
Cash and bank balances including deposits stood at ₹221.85 Cr as of March 31, 2026.
👀 What to Watch
Investors should monitor the margin trajectory of the 'Comfy' hygiene brand now that in-house production has commenced at the Hyderabad plant. The key metric to watch is whether the company can successfully scale its non-pain relief segments beyond the current 40% revenue share.
Rs 9.75 Cr lease rent arrears paid by Amrutanjan following Madras High Court order
Amrutanjan Health Care has paid Rs 9.75 crore in lease rent arrears to the Kapaleeswarar Temple following a dismissal of its writ petition by the Madras High Court. This payment settles a long-standing legal dispute regarding the Tamil Nadu Hindu Religious and Charitable Endowment Act 1959. The outflow is significant, representing approximately 61% of the company's TTM Net Profit of Rs 16 crore. While the company states there is no significant impact on operations, the one-time charge will likely weigh on the immediate quarter's profitability.
Confidence: HIGH
What changedA long-standing legal challenge against lease rent provisions has concluded, resulting in a mandatory one-time payment of arrears.
Why it mattersThe payment is a material cash outflow relative to the company's annual profitability (61% of TTM PAT), although it removes a long-term legal uncertainty from the balance sheet.
Arrears Paid: Rs 9.75 CrTTM Net Profit: Rs 16 CrPayment vs TTM PAT: ~61%Payment vs TTM Revenue: ~2.3%Payment Deadline: 2 August 2026
📅 Short termThe stock may face short-term pressure as the market accounts for the significant one-time hit to the company's cash reserves and quarterly earnings.
📈 Long termLimited structural impact; the core business in pain management and hygiene remains intact, and the resolution of this legal matter prevents further litigation costs.
⚠ Risk flags
- Significant one-time impact on quarterly profitability
- Potential for higher recurring lease expenses going forward
Key Highlights
Total payment of Rs 9,74,67,151 made to Kapaleeswarar Temple on August 1, 2026.
The payment follows a Madras High Court order dated March 17, 2026, which dismissed the company's appeal.
The arrears amount represents approximately 61% of the company's TTM Net Profit (Rs 16 Cr).
The court-mandated deadline for the payment was August 2, 2026.
The dispute originated from Writ Petition No. 35484 of 2005 regarding lease rent regulations.
👀 What to Watch
Investors should monitor the next quarterly financial results to see if this Rs 9.75 Cr is classified as an 'exceptional item' and how it impacts the cash flow statement.
Amrutanjan FY26 Net Profit Rises 14% to ₹57.92 Cr; Recommends ₹2.90 Final Dividend
Amrutanjan Health Care reported a solid financial performance for FY26, with annual revenue from operations growing 11.2% to ₹502.55 crore. Net profit for the full year increased by 13.9% to ₹57.92 crore, even after accounting for exceptional items totaling ₹8.85 crore related to lease rent and labor code impacts. The company has recommended a final dividend of ₹2.90 per share (290% on face value). Additionally, the board approved the rollout of a second phase for its ESOP scheme and appointed new independent directors to the board.
Key Highlights
Annual Revenue from operations increased to ₹502.55 crore in FY26 from ₹451.82 crore in FY25.
Full-year Profit After Tax (PAT) grew 13.9% YoY to ₹57.92 crore.
Recommended a final dividend of ₹2.90 per equity share of ₹1 face value.
Q4 FY26 revenue stood at ₹149.77 crore, a 10.6% growth over Q4 FY25.
Recognized exceptional expenses of ₹7.60 crore for lease rent and ₹1.25 crore for labor code impacts.
👀 What to Watch
Investors can find confidence in the steady double-digit growth in both top-line and bottom-line figures along with a healthy dividend payout. The stock remains a defensive play in the healthcare sector with strong brand equity in the pain management segment.
Amrutanjan FY26 Net Sales Up 11% to ₹502.55 Cr; Profit Before Exceptional Items Rises 25.5%
Amrutanjan Health Care reported a steady 11.23% growth in annual net sales, reaching ₹502.55 crore for FY26. The company's core OTC segment, driven by pain management and the Comfy brand, grew by 13.10% to ₹468.22 crore. Profit before exceptional items saw a robust increase of 25.47% to ₹86.74 crore, although net profit growth was moderated to 13.95% due to one-time legal and labor code provisions. While the Women's Hygiene segment performed well, the Beverages segment (Electro+) faced a decline of 14% during the year.
Key Highlights
Annual Net Sales crossed the ₹500 Cr mark, growing 11.23% YoY to ₹502.55 Cr
Profit Before Tax (before exceptional items) surged 25.47% to ₹86.74 Cr, reflecting improved operational efficiency
The 'Comfy' brand (Women's Hygiene) continues to scale, with the XL variant growing 44% and overall segment sales reaching ₹139.91 Cr
Distribution reach expanded with a 12% increase in total outlet coverage and a 9% growth in the stockist network
Exceptional items included a one-time provision for lease rent disputes and ₹1.25 Cr for new labor code transitions
👀 What to Watch
Investors should focus on the strong growth in high-margin OTC and hygiene segments while monitoring the recovery in the beverages business. The expansion into new personal care categories like razors and nasal sprays provides additional growth levers for FY27.
Amrutanjan Approves ESOP 2 for 44 Employees; 2 Lakh Shares at Rs 502 Grant Price
Amrutanjan Health Care has approved the rollout of the revised second phase of its 2020 ESOP scheme, targeting 44 top and middle management employees. The plan covers 2,00,000 equity shares to be vested over five years from FY27 to FY31, contingent upon meeting specific sales targets. Importantly, the shares will be purchased from the secondary market via an ESOP trust, which prevents the dilution of existing shareholder equity. The grant price is set at Rs 502, representing a 10% discount to the market price as of May 7, 2026.
Key Highlights
Grant of 2,00,000 equity shares to 44 key employees in top and middle management.
Vesting is spread over 5 years (FY27-FY31) and strictly linked to achieving two slabs of sales targets.
Grant price fixed at Rs 502 per share, a 10% discount to the NSE closing price of Rs 558 on May 7, 2026.
Shares will be acquired from the secondary market, ensuring no dilution of the company's equity base.
The final exercise window for the options extends until October 2031.
👀 What to Watch
Investors should view this as a positive move to align management incentives with sales growth without diluting share value. Monitor the company's revenue trajectory over the coming years to gauge the likelihood of these performance-linked options vesting.
Amrutanjan Recommends ₹2.90 Final Dividend and Approves FY26 Audited Results
Amrutanjan Health Care has recommended a final dividend of ₹2.90 per equity share for the financial year 2025-26, pending shareholder approval. The board approved the audited financial results for the year ended March 31, 2026, which received an unmodified opinion from statutory auditors. Significant board changes include the appointment of Mr. Ramaswami Krishnan and the re-appointment of Mr. Muralidharan Swayambunathan as Independent Directors for five-year terms. The company also announced the rollout of the second phase of its 2020 ESOP scheme to align employee interests with shareholders.
Key Highlights
Recommended a final dividend of ₹2.90 per equity share on 2,89,10,630 shares of ₹1 each.
Approved audited financial results for the quarter and year ended March 31, 2026.
Appointed Mr. Ramaswami Krishnan as an Additional Independent Director for a 5-year term.
Approved the rollout of the revised second phase of the ESOP 2020 scheme.
Statutory auditors B S R & Co. LLP issued an unmodified opinion on the annual financial results.
👀 What to Watch
Investors should hold the stock to benefit from the ₹2.90 dividend payout and monitor the full financial statement for growth trends in the healthcare segment.
Amrutanjan Recommends Rs 2.90 Final Dividend and Appoints New Independent Director
Amrutanjan Health Care has recommended a final dividend of Rs 2.90 per equity share for the financial year ending March 31, 2026. The board also approved the appointment of Mr. Ramaswami Krishnan and the re-appointment of Mr. Muralidharan Swayambunathan as Independent Directors for five-year terms. Furthermore, the company is rolling out the second phase of its 2020 Employee Stock Option Scheme (ESOP 2). These announcements coincide with the approval of the company's audited financial results for FY26.
Key Highlights
Recommended a final dividend of Rs 2.90 per equity share of Re 1 face value for FY 2025-26.
Appointed Mr. Ramaswami Krishnan, a qualified CA, CS, and CWA, as an Independent Director for 5 years.
Re-appointed Mr. Muralidharan Swayambunathan as Independent Director for a second term until 2031.
Approved the rollout of the revised second phase of the 2020 Employee Stock Option Scheme (ESOP 2).
Appointed M/s. PKF Sridhar & Santhanam as Internal Auditors for the financial year 2026-2027.
👀 What to Watch
Investors should track the dividend record date following the Annual General Meeting to benefit from the Rs 2.90 payout. The addition of highly qualified professionals to the board and the continuation of ESOP schemes suggest a focus on corporate governance and talent retention.
Amrutanjan Expands into Grooming and Wound Care; Launches Ortho Oil with 66% Pain Reduction
Amrutanjan Health Care has announced a strategic expansion into the grooming segment with the launch of men's and women's razors using Korean technology. The company also introduced 'Amrutanjan Plastry' in the wound care category and a new 'Ortho Pain Relief + Oil' in its core pain management segment. The Ortho Oil is clinically backed, claiming a 66% reduction in pain over an 8-week period. These launches are aimed at diversifying the revenue stream and leveraging the brand's established trust in the domestic market.
Key Highlights
Entry into the grooming segment with three new razor products for men and women using Korean technology
Launch of 'Amrutanjan Plastry' medicated antiseptic plasters in regular and wash-proof formats
Introduction of 'Ortho Pain Relief + Oil' claiming 66% pain reduction in 8 weeks based on clinical evidence
Strategic diversification into high-growth personal care and wound care categories to drive domestic growth
👀 What to Watch
Investors should monitor the market reception and distribution reach of the new grooming range as it competes with established players. Success in these high-margin categories could lead to improved revenue diversification and margin expansion.
Amrutanjan Health Care Clarifies on Reported Rs 9.74 Crore Temple Land Dues
The Exchange has sought clarification from Amrutanjan Health Care regarding a news report alleging Rs 9.74 crore in unpaid dues to the Mylapore Kapaleeswarar Temple. The HR&CE department informed the High Court that the company occupied temple land until 2018 and has outstanding rental arrears. This legal matter involves historical lease obligations and land possession issues. Investors should monitor the company's formal response to determine the potential financial impact and liability.
Key Highlights
Exchange requested clarification on news regarding Rs 9.74 crore in alleged dues.
The dispute involves Mylapore Kapaleeswarar Temple land held by the company until 2018.
HR&CE department has submitted details of the arrears to the High Court.
The company is required to verify the news item and provide an official statement to the exchange.
👀 What to Watch
Investors should wait for the company's official clarification to see if the Rs 9.74 crore is a contested amount or a recognized liability. Monitor for any court orders that might mandate immediate payment or impact the company's cash flow.
Amrutanjan Q3 FY26 Net Sales Up 14.9% to ₹141 Cr; YTD PAT Grows 17% YoY
Amrutanjan Health Care reported a 14.9% YoY increase in Q3 FY26 net sales to ₹141.04 crore, supported by strong performance in the OTC and Comfy segments. While Q3 PAT growth was nearly flat at 1.04% due to higher operational expenses, the nine-month (YTD) performance remains robust with PAT rising 17.02% to ₹41.73 crore. The company is aggressively expanding its distribution, adding 40,000 new chemist outlets and launching premium products like Comfy Night Pads to drive future growth.
Key Highlights
Q3 FY26 Net Sales grew 14.9% YoY to ₹141.04 Cr, while YTD Dec'25 PAT rose 17.02% to ₹41.73 Cr.
The Comfy (Women's Hygiene) brand recorded a strong 22.55% Net Sales growth in Q3 FY26.
Operational efficiency improved significantly with total lines sold increasing by 73% and effective outlet coverage up 10%.
The company added 40,000 new chemist outlets, progressing toward its long-term goal of 100,000 additional outlets.
Pain Management segment maintained momentum with 12% YTD growth, led by a 27% growth in Head Roll-On variants.
👀 What to Watch
Investors should focus on the company's successful diversification into Women's Hygiene and its distribution expansion, which are offsetting the decline in the Rehydration segment. The strong YTD profit growth suggests healthy underlying business momentum despite a high-base effect in Q3 quarterly profits.
Amrutanjan Health Care Sets Feb 7, 2026, as Record Date for Second Interim Dividend
Amrutanjan Health Care Limited has officially fixed February 7, 2026, as the record date for its second interim dividend for the financial year 2025-26. This announcement follows the company's compliance with Regulation 42 of SEBI (LODR) Regulations 2015. Shareholders whose names appear in the register of members or as beneficial owners with NSDL and CDSL on the record date will be eligible for the payout. This marks the second dividend distribution for the current fiscal year, reflecting continued shareholder returns.
Key Highlights
Record date for the Second Interim Dividend is fixed as February 07, 2026
The dividend distribution pertains to the financial year 2025-26
Eligibility is based on beneficial ownership data from NSDL and CDSL as of the record date
Official notification was released on February 03, 2026, following regulatory requirements
👀 What to Watch
Investors seeking to qualify for the dividend should ensure they purchase or hold the shares before the ex-dividend date. Long-term investors should track the total dividend yield for FY26 as part of their income strategy.
Amrutanjan Q3 Net Profit at ₹19.45 Cr; Declares Re. 1 Interim Dividend
Amrutanjan Health Care reported a steady performance for Q3 FY26 with revenue from operations growing 14.9% YoY to ₹141.04 crore. The company declared its second interim dividend of Re. 1 per share for the financial year 2025-26. While net profit saw a marginal increase to ₹19.45 crore, it was slightly impacted by a ₹1.25 crore exceptional charge related to new labour codes. The core OTC and Women's Hygiene segments showed robust growth, while the Beverages segment faced a decline in revenue.
Key Highlights
Declared second interim dividend of Re. 1 per equity share (100% of face value)
Q3 Revenue from operations increased 14.9% YoY to ₹141.04 crore
Net Profit for the quarter stood at ₹19.45 crore versus ₹19.25 crore in the previous year
OTC segment revenue grew 14.3% YoY to ₹100.54 crore, remaining the primary growth driver
Recognized an exceptional item of ₹125.17 lakhs due to the impact of new Labour Codes
👀 What to Watch
Investors should find comfort in the steady growth of the core OTC and Women's Hygiene segments and the consistent dividend payout. The stock remains a stable play in the healthcare and consumer goods space with a strong focus on governance as reflected in its high ESG governance score.
Amrutanjan Q3 Revenue Up 14.9% to ₹141 Cr; Declares ₹1 Interim Dividend
Amrutanjan Health Care reported a 14.9% YoY increase in revenue from operations to ₹141.04 crore for the quarter ended December 31, 2025. Net profit remained relatively flat at ₹19.45 crore compared to ₹19.25 crore in the previous year, primarily due to a ₹1.25 crore exceptional item related to new labor codes. The company declared a second interim dividend of ₹1 per share. Notably, the Women's Hygiene segment showed strong growth, contributing ₹36.68 crore to the top line.
Key Highlights
Revenue from operations grew 14.9% YoY to ₹14,103.87 Lakhs from ₹12,275.15 Lakhs.
Profit After Tax (PAT) stood at ₹1,945.22 Lakhs, up 1.1% YoY despite an exceptional cost.
Declared a second interim dividend of ₹1 per equity share for the financial year 2025-26.
Women's Hygiene segment revenue increased 22.6% YoY to ₹3,667.97 Lakhs.
Recognized an exceptional expense of ₹125.17 Lakhs due to the impact of new labor codes on gratuity and leave encashment.
👀 What to Watch
Investors should take note of the robust top-line growth and the successful scaling of the Women's Hygiene business. The flat net profit is a result of non-recurring regulatory costs, suggesting healthy underlying operational efficiency.
